Search
Purespring Therapeutics raised a $105M series B earlier this month to advance AAV gene therapies for kidney diseases, including both monogenic and non-monogenic diseases
CEO Julian Hanak describes how Purespring focuses on targeting podocytes, a cell type that plays a role in various kidney diseases. Key...
Oct 24, 2024
SecondWave Systems is using low intensity ultrasound to treat inflammatory conditions like RA
Co-Founder & CEO Anuj Bhardwaj describes the device SecondWave has developed and how it is designed to hit the spleen with ultrasound,...
Oct 21, 2024
San Diego based Libra Therapeutics is aiming to boost protein clearance in neurodegenerative diseases by targeting TRPML1
Chief Business Officer Isaac Veinbergs describes this approach and how Libra is focuses on ALS as a first indication.
Oct 21, 2024
Cambridge, MA based Lytica Therapeutics is trying to make antibody-drug conjugates more efficient by designing the antibody portion in a way that makes cells internalize them better
Co-Founder and CEO Rida Mourtada describes how Lytica is adding a peptidic sequence to antibodies to improve their internalization into...
Oct 21, 2024
Since winning a pitch competition a year ago, Synthis Therapeutics has been working out of JLABS' Manhattan location on a TGF-β antibody drug conjugate
Founder & CEO Dori Thomas-Karyat describes why she believes a local delivery approach to the tumor is the solution to the shortcomings...
Oct 21, 2024
Entrepreneur Pierluigi Paracchi on San Raffaele, biotech in Italy, and his company Genenta Science
A leading voice in Italy's biotech community, he describes the world-class work that takes place at his home base of Ospedale San...
Oct 18, 2024
Milan based Enthera Pharmaceuticals is working in the autoimmune space with an asset that targets a unique pathway and that is the result of local research
CEO Lisa Olson describes the IGFBP3/TMEM219 axis and the antibody Enthera has designed to target it, all of which are the result of...
Oct 17, 2024
Lundbeck CEO Charl van Zyl describes the rationale for today's $2.6 billion acquisition of Longboard Pharma
He explains the market opportunity he sees for Bexicaserin and the data that made him comfortable to pull the trigger on the deal today...
Oct 14, 2024
Ghent based Confo Therapeutics is leveraging GPCR expertise as a discovery engine - multiple partners have already signed on to the science
CEO Cedric Ververken walks us through what separates Confo from other GPCR developers, and discusses pipeline programs in pain, obesity,...
Oct 14, 2024
Copenhagen based FluoGuide is working to light up tumors for surgeons by guiding fluorescent molecules to uPAR - a target that has been studied widely in Scandinavia
CEO Morten Albrechtsen describes the rational for this target for this purpose and how they FluoGuide has designed its fluorescent agent....
Oct 11, 2024
IO Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year
Founder and CEO Mai-Britt Zocca explains the rationale for this dual focus and walks us through the lead program that targets PD-L1 and...
Oct 11, 2024
A deep-dive discussion on obesity drug development with Zealand Pharma's CEO Adam Steensberg
He highlights Zealand’s three different approaches to obesity: glucagon/GLP-1, GLP-1/GLP-2, and an amylin analog. Plus, he shares his...
Oct 10, 2024
Ronald Plasterk introduces us to his new company, Tzu Cancer Therapeutics, and the importance of focusing on circulating tumor cells
After selling his previous company, Frame Therapeutics, to CureVac, the Amsterdam based molecular biologist and entrepreneur wants to...
Oct 9, 2024
Leyden Labs is developing antibody-based nasal sprays that aim to stop viruses like flu and covid at the mucosa and with broad protection
Co-founder and CEO Koenraad Wiedhaup describes the shortcomings of today’s vaccines and why the company has chosen this unique approach....
Oct 9, 2024
Edinburgh HQ'd Resolution Therapeutics announced a £63.5M series B this month to advance its pro-regenerative macrophage therapy into further end-stage liver disease studies
CEO Amir Hefni describes how this autologous product is designed to work, the investments Resolution has made in its manufacturing...
Oct 8, 2024
Leiden based ProQR invented the idea of using RNA oligonucleotides to induce ADAR to edit RNA over 10 years ago - the first programs are scheduled to enter the clinic soon
Founder and CEO Daniel de Boer describes ProQR's history in Leiden and why it is an ideal spot for a biotech company to be based. Plus,...
Oct 8, 2024
Oxford, UK based Enara Bio announced a $32.5M series B to further its work developing TCR based therapies that target antigens found in the 'dark genome'
President & CEO Kevin Pojasek describes how the company searches for these novel cancer-specific antigens that are from areas of the...
Oct 4, 2024
Flagship's ProFound Therapeutics is searching for proteins for use as therapeutics and targets beyond those found in the traditional protein coding regions of DNA
CEO John Lepore, who was previously head of research at GSK, describes how the company is screening all proteins that are made by...
Oct 2, 2024
Vor Bio is trying to help AML patients who receive a stem cell transplant to be more amenable to follow-on therapies - they just had key PoC data
President and CEO Robert Ang describes how Vor knocks out CD33 in transplant cells before they are administered so that patients can...
Oct 2, 2024
Mathai Mammen provides an update on the latest at FogPharma, and his philosophy of following the cadence of science, not the calendar
The Chairman and CEO of FogPharma describes the progress the company has made this year, including on the lead β-catenin/TCF4 inhibitor...
Oct 1, 2024
.png){kind=logo}
